Literature DB >> 18514738

Dysregulation of neurosteroids in obsessive compulsive disorder.

K L Bigos, M M Folan, M R Jones, G L Haas, F J Kroboth, P D Kroboth.   

Abstract

Alterations in hormone concentrations, including adrenocorticotropin, corticotropin releasing hormone, and cortisol have been reported in patients with obsessive compulsive disorder (OCD). Dehydroepiandrosterone (DHEA) and its sulfated metabolite, DHEA-S, have not been assessed in patients with OCD. We report 24-h serum DHEA, DHEA-S, and cortisol concentrations in a young man with OCD and 15 healthy young men. Circadian patterns of DHEA and cortisol were markedly different in the subject with OCD than in the control subjects. DHEA and DHEA-S concentrations were substantially higher in the OCD subject than in the control subjects. In contrast, cortisol concentrations were similar in the OCD subject and the control subjects. Future clinical studies are needed to evaluate the significance of DHEA and DHEA-S in OCD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18514738      PMCID: PMC2654381          DOI: 10.1016/j.jpsychires.2008.04.007

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  24 in total

Review 1.  Neuroactive steroids and anxiety disorders.

Authors:  Jean-Michel Le Mellédo; Glen B Baker
Journal:  J Psychiatry Neurosci       Date:  2002-05       Impact factor: 6.186

Review 2.  Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance.

Authors:  M D Majewska
Journal:  Prog Neurobiol       Date:  1992       Impact factor: 11.685

3.  Dexamethasone suppression test in patients with primary obsessive-compulsive disorder and in healthy controls.

Authors:  F Catapano; P Monteleone; M Maj; D Kemali
Journal:  Neuropsychobiology       Date:  1990       Impact factor: 2.328

4.  Endogenous concentrations of DHEA and DHEA-S decrease with remission of depression in older adults.

Authors:  T J Fabian; M A Dew; B G Pollock; C F Reynolds; B H Mulsant; M A Butters; M D Zmuda; A M Linares; M Trottini; P D Kroboth
Journal:  Biol Psychiatry       Date:  2001-11-15       Impact factor: 13.382

Review 5.  The noradrenergic system in pathological anxiety: a focus on panic with relevance to generalized anxiety and phobias.

Authors:  G M Sullivan; J D Coplan; J M Kent; J M Gorman
Journal:  Biol Psychiatry       Date:  1999-11-01       Impact factor: 13.382

6.  Plasma levels of neuroactive steroids are increased in untreated women with anorexia nervosa or bulimia nervosa.

Authors:  P Monteleone; M Luisi; B Colurcio; E Casarosa; P Monteleone; R Ioime; A R Genazzani; M Maj
Journal:  Psychosom Med       Date:  2001 Jan-Feb       Impact factor: 4.312

7.  Positive correlation between anxiety severity and plasma levels of dehydroepiandrosterone sulfate in medication-free patients experiencing a major episode of depression.

Authors:  Cheng-Cheng Hsiao
Journal:  Psychiatry Clin Neurosci       Date:  2006-12       Impact factor: 5.188

8.  Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder.

Authors:  M Altemus; T Pigott; K T Kalogeras; M Demitrack; B Dubbert; D L Murphy; P W Gold
Journal:  Arch Gen Psychiatry       Date:  1992-01

9.  Abnormal dexamethasone suppression test in primary obsessive-compulsive patients: a confirmatory report.

Authors:  J A Cottraux; M Bouvard; B Claustrat; C Juenet
Journal:  Psychiatry Res       Date:  1984-10       Impact factor: 3.222

10.  The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABAA receptor.

Authors:  M D Majewska; S Demirgören; C E Spivak; E D London
Journal:  Brain Res       Date:  1990-08-27       Impact factor: 3.252

View more
  5 in total

Review 1.  Circadian rhythms in obsessive-compulsive disorder.

Authors:  Klaus W Lange; Katharina M Lange; Joachim Hauser; Lara Tucha; Oliver Tucha
Journal:  J Neural Transm (Vienna)       Date:  2012-04-28       Impact factor: 3.575

2.  Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: a 3 month follow-up case series.

Authors:  Michele Fornaro
Journal:  Ann Gen Psychiatry       Date:  2011-02-28       Impact factor: 3.455

Review 3.  Animal models of obsessive-compulsive disorder: utility and limitations.

Authors:  Pino Alonso; Clara López-Solà; Eva Real; Cinto Segalàs; José Manuel Menchón
Journal:  Neuropsychiatr Dis Treat       Date:  2015-08-04       Impact factor: 2.570

4.  Increased serum brain-derived neurotrophic factor and adrenocorticotropic hormone levels are associated with obsessive compulsive disorder in medication‑free children.

Authors:  Ayhan Bilgiç; Merve Sertdemir; İbrahim Kılınç; Ömer Faruk Akça
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-01-02       Impact factor: 4.785

5.  Neurosteroid Levels in Patients with Obsessive-Compulsive Disorder.

Authors:  Lale Gonenir Erbay; Sukru Kartalci
Journal:  Psychiatry Investig       Date:  2015-09-30       Impact factor: 2.505

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.